Dianthus Therapeutics (DNTH)
Develops self-injected complement and dual-pathway therapies for severe autoimmune diseases.
Something off on this page? Send us feedback.
Develops subcutaneous autoimmune therapies led by active-C1s antibody claseprubart for neuromuscular diseases, with dual-pathway fusion proteins for rheumatologic conditions. Revenue comes from licensing rather than product sales while the pipeline remains subject to clinical and regulatory approval.
Develops autoimmune therapies around selective immune-pathway inhibition and infrequent subcutaneous self-administration. Claseprubart, an active-C1s monoclonal antibody, is in late-stage trials for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, alongside a mid-stage trial in multifocal motor neuropathy. DNTH212 combines BDCA2 and BAFF/APRIL inhibition for Sjögren’s disease, systemic lupus erythematosus, and dermatomyositis, while preclinical DNTH312 combines active-C1s and BAFF/APRIL inhibition.
Runs a single U.S. operating segment from New York, using global studies and Greater China license partners. Its programs span neuromuscular and rheumatologic disease, with molecular engineering focused on longer half-lives and low-volume self-injection. No candidate is approved and no product sales have been generated; development depends on clinical results, regulatory clearance, licensed rights, and third-party manufacturers.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 4, 2026 | Citigroup | Initiate | Rating: — | |
| Aug 6, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $130 | Target: $158 |
| Aug 5, 2026 | Wedbush | Reiterate | Rating: —Target: $55 | Target: $122 |
| Aug 5, 2026 | Raymond James | Reiterate | Rating: —Target: $125 | Target: $131 |
| Jun 10, 2026 | Jefferies | Target | Target: $98 | Target: $132 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $886.8M · Total debt $1.3M · Total assets $1.21B · Shareholders' equity $1.17B
- Revenue
- $761.0K
- Operating income
- −$61.5M
- Net income
- −$50.2M
No dividends on record.
| Institutions | ≈ 115.36% | 64.52M shares | |
|---|---|---|---|
| 279 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.19% | 106.1K shares | |
| 3 holders · as of Sep 3, 2026 | |||
| Adds to | 115.55% | ||
55.93M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 115.55%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.66% | 8.20M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.37% | 4.12M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 6.95% | 3.89M | as of Jun 30, 2026 |
Wellington Management Group LLPInstitution | 5.77% | 3.23M | as of Jun 30, 2026 |
Sirenia Capital Management LPInstitution | 5.00% | 2.80M | filed May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 17, 2026 | Edward Carr | officer: CHIEF ACCOUNTING OFFICER | −20,000 | $101.38 |
| Sep 1, 2026 | Simrat Randhawa | officer: EVP, Head of R&D | −23,124 | $106.41 |
| Aug 19, 2026 | Simon Read | director | −2,778 | $117.55 |
| Aug 10, 2026 | Anne McGeorge | director | −7,750 | $109.01 |
| Aug 10, 2026 | Adam M. Veness | officer: SVP, General Counsel and Sec. | −16,167 | $110.38 |
- argenx (ADR)
Vyvgart (efgartigimod) FcRn antagonist approved in gMG and CIDP; $4.2B in 2025.
- AstraZeneca (ADR)
Alexion complement franchise — Soliris/Ultomiris (C5, IV-only) approved in gMG.
- Sanofi (ADR)
Anti-C1s mAb riliprubart; CIDP Phase 3 MOBILIZE stopped for futility Jun 2026.
- Annexon
Anti-C1q mAb tanruprubart; GBS Phase 3 complete; EMA MAA filed Jan 2026.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics | $93.82 | −4.61% | $5.50B | — | — | 2,889.3 | +294.3% |
| argenx (ADR) | $950.33 | −1.40% | $59.94B | 36.7 | — | 10.0 | +197.0% |
| AstraZeneca (ADR) | $165.31 | −1.82% | $261.12B | 25.3 | 15.5 | 4.3 | +6.4% |
| Sanofi (ADR) | $41.61 | −2.13% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Annexon | $3.96 | −5.20% | $684.9M | — | — | — | — |
| Median | 36.7 | 15.5 | 4.3 | +11.2% |